Dalpiciclib plus abiraterone for advanced prostate cancer
Part of Cancer clinical trials.
This trial tests a new combination of drugs (dalpiciclib isethionate with abiraterone and prednisone) against a placebo plus standard therapy for men with advanced prostate cancer that has spread and still responds to hormone treatment. The goal is to see if the new combination works better at controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and male.
- You must have a specific type of prostate cancer called adenocarcinoma that has spread to other parts of the body (metastatic).
- Your cancer must still respond to hormone therapy (hormone-sensitive), meaning you haven't yet had a lot of prior treatments.
- You must not have taken certain medications before, such as CDK4/6 inhibitors (like Ibrance) or newer hormone drugs (like Enzalutamide).
- You should not have tumors in your brain or a history of severe lung conditions like interstitial pneumonia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (darxicilib and abiraterone) for prostate cancer that has spread and stopped responding to standard hormone therapy. It may be an option if you have already tried a newer hormone therapy like enzalutamide or apalutamide and it stopped working.
This trial tests dalpiciclib together with hormone (endocrine) therapy in people with HR-positive, HER2-negative advanced breast cancer whose cancer has already responded poorly to a prior CDK4/6 inhibitor. It aims to see if this combination can better control the cancer after that earlier treatment has failed.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial tests a combination of two targeted drugs (dalpiciclib and an HDAC inhibitor) for people with HR+/HER2- advanced breast cancer whose disease has progressed after prior CDK4/6 inhibitor treatment. The goal is to see if this new combination can help control the cancer.
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Hear when a new High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.